CA2149150C - Injectable taxol composition with improved stability - Google Patents

Injectable taxol composition with improved stability Download PDF

Info

Publication number
CA2149150C
CA2149150C CA002149150A CA2149150A CA2149150C CA 2149150 C CA2149150 C CA 2149150C CA 002149150 A CA002149150 A CA 002149150A CA 2149150 A CA2149150 A CA 2149150A CA 2149150 C CA2149150 C CA 2149150C
Authority
CA
Canada
Prior art keywords
acid
taxol
acidifying agent
pharmaceutical formulation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002149150A
Other languages
French (fr)
Other versions
CA2149150A1 (en
Inventor
David R. Carver
Timothy R. Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma USA Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2149150(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Priority to CA002308082A priority Critical patent/CA2308082A1/en
Publication of CA2149150A1 publication Critical patent/CA2149150A1/en
Application granted granted Critical
Publication of CA2149150C publication Critical patent/CA2149150C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

A composition of taxol and polyethoxylated castor oil is pH balanced to have a pH less man 8.1 to improve stability. This composition can include an acid, preferably citric acid, to adjust the pH value. The invention includes a method of formulating a taxol solution for injection by mixing an acid with a carrier material, such as castor oil, to form a carrier solution after which taxol is mixed with the carrier solution to form the taxol solution at a pH of less than 8.1. The method may include the step of slurrying the taxol in alcohol before mixing with the carrier solution.

Description

INJECTABI~E COMPOSITION
This invention relates to a solution of taxol having improved stability.
Taxol is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
In 1977, taxol was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-1 mammary tumor xenograft.
Taxol is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Taxol employs a different mechanism of action since it appears to shift the equilibrium of polymerization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
After extensive preclinical screening in mouse tumor models, taxol entered clinical trials in 1983.
Over the past few years, taxol has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefiting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
For further information, reference may be made to the U.S. National Cancer Institute's Clinical Brochure for Taxol, revised July 1991, and papers presented at the Second National Cancer Institute Workshop on Taxol and Taxus held in Alexandria, Virginia USA on September 23-24, 1992.
It is a disadvantage of a known formulation that the taxol therein degrades, with the result that the shelf life of the formulation is unsatisfactory, and there is therefore a need for a taxol solution of improved stability.
In accordance with one aspect of the present invention, there is provided an improvement in a pharmaceutical formulation adapted for use in treating cancer comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent added to the pharmaceutical formulation in a proportion such that the composition has a resulting pH less than or equal to 7Ø
The present invention provides, in another aspect of the invention, an improvement in an anhydrous pharmaceutical formulation comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent mixed in a proportion such that said pharmaceutical formulation has a resulting pH of about 7 or less.
In accordance with an additional aspect of the invention, there is provided a pharmaceutical taxol composition comprising: taxol; polyethoxylated castor oil; and anhydrous citric acid in sufficient amounts to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for 7 days.
The present invention provides, in a yet further aspect of the invention, a pharmaceutical taxol composition comprising: taxol; polyethoxylated castor oil; and acetic acid in sufficient amounts to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for 7 days.
In an additional aspect of the invention, there is provided an article of manufacture comprising a container and a pharmaceutical formulation contained therein, the pharmaceutical formulation comprising a pharmaceutically-acceptable carrier, taxol, and an acidifying agent mixed in proportion such that the pharmaceutical formulation has a resulting pH of about 7 or less.
A further aspect of the present invention provides a method of formulating a taxol solution for injection in which the taxol does not readily degrade, comprising the following steps: mixing acid with a carrier material to form a first carrier solution; and mixing taxol with the first carrier solution to form a taxol solution whereby the taxol in the taxol solution does not readily degrade.
In a further aspect of the invention, there is provided a method for improving the stability of a pharmaceutical taxol solution over an extended period, comprising the steps of: providing a formulation comprising taxol, a pharmaceutically-acceptable carrier, and an acidifying agent; and storing the formulation in a container for at least 7 days.
The present invention, in a yet further aspect of the invention, provides a method of making a pharmaceutical carrier solution, useful in making a formulation comprising taxol, comprising the following steps: obtaining a pharmaceutical carrier material, and mixing an acid with the carrier material to yield a carrier solution.

3a An additional aspect of the present invention provides an improvement in a pharmaceutical carrier composition useful for combining with taxol to yield a taxol formulation, the improvement comprising mixing an acid with the carrier composition.
Accordingly, in a general aspect the invention provides a solution containing taxol, cremophor ELTM
and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid. Acids in the form of powders, for example citric acid, are preferred over those which contain water, for example sulfuric acid. The most preferred acid for use in accordance with the present invention is citric acid but a wide range of acids may be used including the following:
Citric acid - monohydrous Citric acid - anhydrous Citric acid - hydrous Acetic acid Formic acid Ascorbic acid Aspartic acid Benzene sulphonic acid Benzoic acid Hydrochloric acid Sulphuric acid Phosphoric acid Nitric acid Tartaric acid Diatrizoic acid Glutamic acid Lactic acid Malefic acid Succinic acid 3b Due to its limited solubility in water, Taxol is usually prepared and administered in a vehicle containing cremophor ELTM (a polyethoxylated castor oil which acts as a solubilizer) and ethanol. A
commercially available solution supplied by Bristol-Myers Squibb (BMS) is formulated with these components and has a pH of 9.1.
As indicated above, the invention essentially teaches addition of an acid to a taxol formulation to adjust its pH into the range 1 to 8, preferably 5 to 7.
In a preferred procedure adopted by the applicant, which it will be clearly understood is non-limiting, the following steps were carried out:
Mixing Instructions Citric acid was dissolved in absolute alcohol, using a ratio of 8 mls of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.

Cremophor EL was weighted out into the main mixing vessel.

Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid. Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes. The taxol was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of taxol. The slurried taxol was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol. Solution 3 was adjusted to 750 of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until 3c completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
Example 1 A solution was prepared with the following formulation:
Formulation: (Sample 1):
Cremophor EL 0.5 mL
Citric Acid (Anhydrous) 2.0 mg Taxol 6.0 mg Absolute Alcohol to 1.0 mL

W~ 94/12031 ~ ~ '~ '~. ~ 0 PCT/ZJS931i1209 The gH of this solution was determined as 6.1.
The stability of this sample was compared with a sample prepared by the formulation stated in the ICI Taxol Clinical brochure (as follows) which had a pH of 9.1. (Sample 2) Sample 2 per mL
Taxol 6 mg ~remophor EL 0.5 mL
Absolute Alcohol to ~. mL
The solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.
The solutions were stored at 40°C for 7 (seven) days and the stability resul~cs are shown in Table 1.
S~mp~.e 1 Samola ~
PH 6.2 9:0 Potency 95.6 X6.7 Major individual 003% 5.1% impurity Total impurities 2.0% 12.2%
Clearly Sample 1 shored significantly increased stability over Sample 2.
lExam~ple 2 A solution was prepared with the follo~nring formulation:
Formulae.on° (Sample 3~
Cremophor HL 0.5 mL
Tax.ol 6.0 mg Absolute Hthanol to 1 mL
pH adjusted to 6.6 with 1: OM Acetic Acid.
The so3.ution was filled into clear type z glass 5 mL
~I vials and sealed with rubber bungs.
The solution was stored at 40°C for 7 days.
The stab3.lity results obtained are compared to those seen . with Sample 2.
Sam S amt~l a 2 ~H 6.7 ~.0 Fotency 97.5 X6.7 Major individual 0.3% 5.1% impurity . , ,.. .:: ., . : :.,. ". , . . . : ,,. . .,.:- . ; . . . ; -: :- . . :: ; ;
«-- ~ . .. . ; ; :: . . . ~, ~ ~ : ,:.
a. ',.....: . .. .. -... ...... . .. ...... ~ . :., . ..:....... .,...... ..
.....:.. ,. . . . . .. . ,:... . ; ...
t .. : - :... ,..:.,.~. :. ...~.. :. ~.~. ...,.', ,~.:..:; ".....w... ~.,~.r.
. ~ .,..,,.,.. .... , . ,:...,:..., . .....:..~ ;..~..._ ~. ~.;...., . ......
~i ........:~.~ '~ ..~~-...... ;,.... ..
r .:
i a..~;<... ;;~;. ,.,..,.. ' '.~ ....;-~.'. .:,..... .::,..~, ,:'.'-;', .
~,.:...w . , ,... ~..:::... ..;.~;:.; , .,~,,.,.,,..,. ...~; ,..:
,r a l... ::' ~,~.....: ".:,._.:.. :,::.: . ';~.;~.; _...;,.:..., , :..,.,: ,.
,:.;. . ~.:,::~..~ , ,:..,";.,.. ..;~.,~ .:',~....,.. n,...~v,,.'.,..; ,~ , .t~.4.....?:., ..~ ., ~.,-~:, . ~...., .. .: ...,~... ~-.... ;-..: ~,.. ~ .
,........ .. . . .... .". ~... :..:....~. n .. . ..... ..., ..:.~ ~..,... .
..,:.. ... ._ .....,., ..~~. .. .. ..,. . .,.

V6~0 94112031 ~ PCT/US93/11209 Total impurities 2.3~ 12.2 Again the significantly superior stability of the formulation according to the invention (Sample 3) is evident.
It will be clearly understood that the invention in its general aspects is not limited to the specific details referred to hereinabove.

Claims (56)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. In a pharmaceutical formulation adapted for use in treating cancer comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent added to said pharmaceutical formulation in a proportion such that said composition has a resulting pH less than or equal to 7Ø
2. The improved pharmaceutical formulation of claim 1 wherein said composition has a pH of between 5 and 7, inclusively.
3. The improved pharmaceutical formulation of claim 1 including ethanol as a constituent thereof.
4. The improved pharmaceutical formulation of claim 3 wherein said composition has a pH of between 5 and 7, inclusively.
5. The improved pharmaceutical formulation of any one of claims 1 to 4, wherein said acidifying agent is a mineral acid.
6. The improved pharmaceutical formulation of any one of claims 1 to 4, wherein said acidifying agent is an organic acid.
7. The improved pharmaceutical formulation of any one of claims 1 to 9, wherein said acidifying agent is acetic acid.
8. The improved pharmaceutical formulation of any one of claims 1 to 4, wherein said acidifying agent is citric acid.
9. The improved pharmaceutical formulation claimed in claim 8, wherein said citric acid is anhydrous.
10. In an anhydrous pharmaceutical formulation comprising taxol and polyethoxylated castor oil, the improvement comprising an acidifying agent mixed in a proportion such that said pharmaceutical formulation has a resulting pH of about 7 or less.
11. The improved pharmaceutical formulation of claim 10, wherein the pH is from about 7 to about 5.
12. The improved pharmaceutical formulation of claim 10 or 11, wherein said acidifying agent is a mineral acid.
13. The improved pharmaceutical formulation of claim 10 or 11, wherein said acidifying agent is an organic acid.
14. The improved pharmaceutical formulation of claim 10 or 11, wherein said acidifying agent is acetic acid.
15. The improved pharmaceutical formulation of claim 10 or 11, wherein said acidifying agent is citric acid.
16. The improved pharmaceutical formulation of claim 15, wherein said citric acid is anhydrous.
17. A pharmaceutical taxol composition comprising:
taxol;
polyethoxylated castor oil; and anhydrous citric acid in sufficient amounts to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for 7 days.
18. A pharmaceutical taxol composition comprising taxol;
polyethoxylated castor oil; and acetic acid in sufficient amounts to improve the stability of the taxol such that at least 95% of the taxol potency is retained when the composition is stored at 40°C for 7 days.
19. An article of manufacture comprising a container and a pharmaceutical formulation contained therein, said pharmaceutical formulation comprising a pharmaceutically-acceptable carrier which is a polyethoxylated castor oil, taxol, and an acidifying agent mixed in proportion such that said pharmaceutical formulation has a resulting pH of about 7 or less.
20. The article of manufacture of claim 19 further comprising instructions for administering said pharmaceutical formulation to a patient.
21. The article of manufacture of claim 20, wherein said acidifying agent is a mineral acid.
22. The article of manufacture of claim 20, wherein said acidifying agent is an organic acid.
23. The article of manufacture of claim 20, wherein said acidifying agent is acetic acid.
24. The article of manufacture of claim 20, wherein said acidifying agent is citric acid.
25. The article of manufacture of claim 24, wherein said citric acid is anhydrous.
26. A method of formulating a taxol solution for injection in which the taxol does not readily degrade, comprising the following steps:
mixing acid with a carrier material which is a polyethoxylated castor oil to form a first carrier solution; and mixing taxol with the first carrier solution to form a taxol solution having a pH of less than or equal to 7.0 whereby the taxol in the taxol solution does not readily degrade.
27. The method of claim 26, wherein said acid is a mineral acid.
28. The method of claim 26, wherein said acid is an organic acid.
29. The method of claim 26 wherein said acid is acetic acid.
30. The method of claim 26 wherein said acid is citric acid.
31. The method of claim 30 wherein said citric acid is anhydrous.
32. The method of any one of claims 27 to 31 including the step of slurrying said taxol in alcohol before mixing said taxol with the first carrier solution.
33. The method of any one of claims 26 to 32, wherein said taxol solution has a pH of between 5 and 7, inclusively.
34. A method for improving the stability of a pharmaceutical taxol solution over an extended period, comprising the steps of:
providing a formulation comprising taxol, a pharmaceutically-acceptable carrier which is a polyethoxylated castor oil, and an acidifying agent conferring to the solution a pH of less than or equal to 7.0; and storing said formulation in a container for at least 7 days.
35. The method of claim 34, wherein said formulation is anhydrous.
36. The method of claim 34 or 35, wherein said acidifying agent is a mineral acid.
37. The method of claim 34 or 35, wherein said acidifying agent is an organic acid.
38. The method of claim 34 or 35, wherein said acidifying agent is citric acid.
39. The method of claim 34 or 35, wherein said acidifying agent is acetic acid.
40. The method of claim 38, wherein said citric acid is anhydrous.
41. A method of making a pharmaceutical carrier solution, useful in making a formulation comprising taxol, comprising the following steps:

obtaining a pharmaceutical carrier material which is a polyethoxylated castor oil; and mixing an acid with said carrier material to yield a carrier solution having a resulting pH of less than or equal to 7Ø
42. The method of claim 41, wherein said acid is a mineral acid.
43. The method of claim 41, wherein said acid is an organic acid.
44. The method of claim 43, wherein said acid is citric acid.
45. The method of claim 44, wherein said citric acid is anhydrous.
46. The method of claim 43, wherein said acid is acetic acid.
47. The method of claim 41, wherein said carrier solution has a resulting pH of from about 7 to about 5.
48. In a pharmaceutical carrier composition containing polyethoxylated castor oil and useful for combining with taxol to yield a taxol formulation, the improvement comprising mixing an acid with said carrier composition in such an amount as to yield a pH of less than or equal to 7Ø
49. The improved pharmaceutical carrier composition of claim 48, wherein said carrier composition further comprises ethanol.
50. The improved pharmaceutical carrier composition of claim 48 or 49, wherein said acid is a mineral acid.
51. The improved pharmaceutical carrier composition of claim 48 or 49, wherein said acid is an organic acid.
52. The improved pharmaceutical carrier composition of claim 51, wherein said organic acid is citric acid.
53. The improved pharmaceutical carrier composition of claim 52, wherein said citric acid is anhydrous.
54. The improved pharmaceutical carrier composition of claim 51, wherein said organic acid is acetic acid.
55. The improved pharmaceutical carrier composition of any one of claims 48 to 54, having a resulting pH of about 7 or less.
56. The improved pharmaceutical carrier composition of claim 55, having a resulting pH of from about 7 to about 5.
CA002149150A 1992-11-27 1993-11-18 Injectable taxol composition with improved stability Expired - Lifetime CA2149150C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002308082A CA2308082A1 (en) 1992-11-27 1993-11-18 Injectable compostion

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
AUPL6074 1992-11-27
US99550192A 1992-12-22 1992-12-22
US07/995,501 1992-12-22
PCT/US1993/011209 WO1994012031A1 (en) 1992-11-27 1993-11-18 Injectable composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002308082A Division CA2308082A1 (en) 1992-11-27 1993-11-18 Injectable compostion

Publications (2)

Publication Number Publication Date
CA2149150A1 CA2149150A1 (en) 1994-06-09
CA2149150C true CA2149150C (en) 2000-08-01

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002149150A Expired - Lifetime CA2149150C (en) 1992-11-27 1993-11-18 Injectable taxol composition with improved stability
CA002308082A Abandoned CA2308082A1 (en) 1992-11-27 1993-11-18 Injectable compostion

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002308082A Abandoned CA2308082A1 (en) 1992-11-27 1993-11-18 Injectable compostion

Country Status (12)

Country Link
US (7) US5733888A (en)
EP (4) EP0835657B1 (en)
JP (1) JP2880292B2 (en)
AT (2) ATE169216T1 (en)
AU (1) AU5612694A (en)
CA (2) CA2149150C (en)
DE (2) DE69320206T2 (en)
DK (2) DK0674510T3 (en)
ES (2) ES2224200T3 (en)
GR (1) GR3027724T3 (en)
PT (1) PT835657E (en)
WO (2) WO1994012031A1 (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69320206T2 (en) * 1992-11-27 1999-02-11 Napro Biotherapeutics Inc INJECTABLE COMPOSITION CONTAINING PACLITAXEL
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (en) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Stabilization solvent, pharmaceutical composition containing it, and process for its preparation.
NL9500340A (en) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Stabilized paclitaxel solution and pharmaceutical preparation containing said solution
DE19536165A1 (en) * 1995-09-28 1997-04-03 Basf Ag Process for cleaning alkoxylated fats
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CN1245423A (en) 1996-12-30 2000-02-23 巴特勒纪念研究院 Formulation and method for treating neoplasms by inhalation
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BE1011216A3 (en) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Pharmaceutical form for the administration of paclitaxel, method of preparation of a composition paclitaxel ready to employment and use thereof.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
WO2000023070A1 (en) 1998-10-20 2000-04-27 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR100856353B1 (en) 1999-05-14 2008-09-04 니리어스 파마슈티컬즈, 인크. Novel interleukin-1 and tumor necrosis factor-?modulators, syntheses of said modulators and methods of using said modulators
DE19925211B4 (en) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit for the preparation of a formulation of paclitaxel
CO5271755A1 (en) * 2000-01-20 2003-04-30 Baker Norton Pharma PURIFICATION OF POLYOXYETHYLED CASTOR OILS WITH ACTIVATED CARBON
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
ATE439441T1 (en) 2000-02-23 2009-08-15 Life Technologies Corp MODIFIED FLUORESCENT PROTEINS
JP4922507B2 (en) * 2000-08-10 2012-04-25 武田薬品工業株式会社 Pharmaceutical composition
EP1310248A4 (en) 2000-08-10 2008-05-21 Takeda Pharmaceutical Pharmaceutical composition
JP4395549B2 (en) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Marine actinomycete taxa for the discovery of drugs and fermentation products
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1379231A2 (en) 2001-04-06 2004-01-14 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (en) * 2001-09-10 2007-11-08 주식회사 중외제약 Injectable composition of paclitaxel
JP2005515187A (en) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド Process for the preparation of pharmaceutical compositions using polyoxyethylated castor oil
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2003053350A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CZ294371B6 (en) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1530465B2 (en) 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ATE374767T1 (en) * 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF AND A METHOD FOR PRODUCING DEHYDROPHENYLAHISTINES AND ANALOGUES THEREOF
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
WO2004043390A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
EP1606065A4 (en) * 2003-02-11 2010-09-29 Univ Northwestern Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
KR20060026052A (en) * 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
PL2441767T3 (en) * 2003-06-20 2015-11-30 Univ California Salinosporamides and methods for use thereof
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
PT1694660E (en) * 2003-12-12 2009-07-16 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
BRPI0506535A (en) * 2004-01-23 2007-02-27 Nereus Pharmaceuticals Inc Bisindole pyrroles useful as antimicrobial agents
KR20050099311A (en) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) Composition for injection comprising anticancer drug
EP2025679A3 (en) 2004-04-30 2009-07-08 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
DK1830838T3 (en) 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Compositions and Methods for Treating Neoplastic Diseases
KR20060121721A (en) * 2005-05-23 2006-11-29 주식회사 중외제약 Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
EP2311795A3 (en) 2005-07-21 2011-12-28 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators
SI3311805T1 (en) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP1928435B8 (en) 2005-08-31 2019-03-20 Abraxis BioScience, LLC Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof
BRPI0600194A (en) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (en) * 2007-02-19 2008-08-22 Centre Nat Rech Scient NEW INDOLE-DERIVED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
MX2010012341A (en) 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Salinosporamide derivatives as proteasome inhibitors.
ES2344674B1 (en) * 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (en) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc Taxane pro-emulsion formulations and methods making and using the same
NZ603828A (en) 2010-05-03 2015-09-25 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2691075A1 (en) 2011-03-29 2014-02-05 Sanofi Otamixaban formulations with improved stability
EP2731938A4 (en) * 2011-07-11 2014-12-24 Biolyse Pharma Corp Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
AU2014239516B2 (en) * 2013-03-15 2019-01-24 Epizyme, Inc. Injectable formulations for treating cancer
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
CN106794986A (en) 2014-09-02 2017-05-31 布平德尔·辛格 Deuterate or non-deuterate molecule and pharmaceutical preparation
AU2015317509A1 (en) * 2014-09-17 2017-03-16 Epizyme, Inc. Injectable formulations for treating cancer
EP3912620A1 (en) 2014-10-08 2021-11-24 Pacific Northwest Research Institute Methods and compositions for increasing the potency of antifungal agents
MX2017011374A (en) 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation.
BR112017018964A2 (en) 2015-03-06 2018-05-22 Beyondspring Pharmaceuticals Inc use of plinabulin and methods to treat brain tumor
ES2910035T3 (en) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Plinabulin Compositions
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
CN108778267A (en) 2016-02-08 2018-11-09 万春药业公司 Including the composition of Tucaresol or its analog
KR20190015361A (en) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing neutropenia
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Tubulin binding compounds and their therapeutic use
CN110381938A (en) 2017-02-01 2019-10-25 大连万春布林医药有限公司 The method for reducing neutrophil leucocyte deficiency disease
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP7350015B2 (en) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Compositions and methods for reducing thrombocytopenia due to administration of plinabulin
JP2021519367A (en) 2018-03-28 2021-08-10 ハーバライフ・インターナショナル・オブ・アメリカ・インコーポレイテッド Acetylation of polysaccharides
MX2021004128A (en) * 2018-10-16 2021-06-15 US Nano Food & Drug INC Intratumor injection formulation.
AU2021257738A1 (en) 2020-04-13 2022-05-19 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (en) * 1971-08-06 1980-01-19
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
JPH05500531A (en) * 1990-02-15 1993-02-04 ピー　キュー　コーポレーション Method for treating frying oil using alumina and amorphous silica composition
TW223634B (en) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
DE69320206T2 (en) * 1992-11-27 1999-02-11 Napro Biotherapeutics Inc INJECTABLE COMPOSITION CONTAINING PACLITAXEL
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Also Published As

Publication number Publication date
US6306894B1 (en) 2001-10-23
ATE169216T1 (en) 1998-08-15
DK0835657T3 (en) 2005-01-10
WO1994012030A1 (en) 1994-06-09
US20030065022A1 (en) 2003-04-03
ATE274347T1 (en) 2004-09-15
US6770670B2 (en) 2004-08-03
US6140359A (en) 2000-10-31
EP0674510B1 (en) 1998-08-05
JP2880292B2 (en) 1999-04-05
DE69320206D1 (en) 1998-09-10
EP0674510A1 (en) 1995-10-04
CA2149150A1 (en) 1994-06-09
EP0835657A1 (en) 1998-04-15
JPH08503945A (en) 1996-04-30
DE69320206T2 (en) 1999-02-11
ES2224200T3 (en) 2005-03-01
AU5612694A (en) 1994-06-22
EP1500393A1 (en) 2005-01-26
DK0674510T3 (en) 1999-05-10
CA2308082A1 (en) 1994-06-09
EP0674510A4 (en) 1995-08-12
PT835657E (en) 2004-11-30
EP0835657B1 (en) 2004-08-25
DE69333605T2 (en) 2005-02-03
US5972992A (en) 1999-10-26
EP1384474A1 (en) 2004-01-28
US5733888A (en) 1998-03-31
GR3027724T3 (en) 1998-11-30
WO1994012031A1 (en) 1994-06-09
US20040204479A1 (en) 2004-10-14
ES2119996T3 (en) 1998-10-16
US5977164A (en) 1999-11-02
DE69333605D1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
CA2149150C (en) Injectable taxol composition with improved stability
KR100371062B1 (en) Injectable taxi brush compositions with improved stability and methods of formulating them
AU614710B2 (en) Stabilized drug compositions
JP4805599B2 (en) Paclitaxel aqueous injection solution and preparation method thereof
IE51637B1 (en) Pharmaceutical preparation
JP5334937B2 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
AU2002351169B2 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US7658943B2 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
IE910986A1 (en) Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-¹containing preparation and stabilizing method therefor
RU2279873C2 (en) Vinorelbin-containing oral pharmaceutical composition for soft capsule and method for treatment
GB2388025A (en) Kit for preparing a formulation of paclitaxel

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131118